INTRODUCTION HIV is associated with damage of Epstein-Barr virus (EBV) viral setpoint by developing cell immunosuppression, thereby contributes to the EBV reactivation. Loss of EBV infection control results to increased population of EBV infected B lymphocytes ^ development of lymphoproliferative disorders (1). EBV viral load (VL) has been studied as biomarker in EBV+ non HIV associated lymphomas and HIV-NHLs. In HIV associated lymphoma EBV viral load is higher than in control group and associated with an increased risk of developing lymphoma (3, 4, 5). The aim of this study is characterization of viral load in HIV-LNH/LH. MATERIAL AND METHODS 147 patients between 2008 and 2014 (ANRS CO-16 Lymphovir Cohort) (2): 59 HIV-positive Hodgkin lymphoma (HIV-HL), 86 HIV-positive non Hodgkin lymphoma (HIV-NHL) 2 HIV-NHL+ HL Principal investigators: Caroline Besson and Dominique Costagliola DNA isolation: 200 ^l of whole blood (WB) or plasma using MagNA Pure LC instrument (DNA Isolation kit, Roche Diagnostics) or NucliSENS easyMAG instrument (Biomérieux) Real time PCR: Kit: EBV R-gene™ Quantification Kit ® (Biomérieux) Amplification: Light Cycler 480 (Roche Diagnostics) Expression: number of EBV DNA copies by mL of sample Sensitivity: 200 viral copies/mL The cutoff of 200 viral copies/mL= EBV DNA load as + or -. RESULTS МЕДИЦИНСКИЙ АКАДЕМИЧЕСКИЙ ЖУРНАЛ, 2016 г., ТОМ 16, № 3 115 DISCUSSION • No correlation between EBV-VL and survival without progression HIV-LH/LNH. • EBV DNA was more often detected in WB, than in plasma. • EBV DNA viral load declined significantly in plasma but not in WB ^ clearance of cell-free • EBV DNA from the tumor? • Plasma could be more adapted to monitor HIV-LNH/HV. CONCLUSION Both HIV and EBV (and not only EBV alone) act as cofactors in lymphomagenesis.

Touyana Semenova

Irkutsk State Medical University; IBS, UMR 5075 CEA-CNRS-Univ. Grenoble Alpes; Grenoble University Hospital, Univ. Grenoble-Alpes

Irkutsk, Russia; Grenoble, France

Raphaële Germi

IBS, UMR 5075 CEA-CNRS-Univ. Grenoble Alpes; Grenoble University Hospital, Univ. Grenoble-Alpes

Grenoble, France

Julien Lupo

IBS, UMR 5075 CEA-CNRS-Univ. Grenoble Alpes; Grenoble University Hospital, Univ. Grenoble-Alpes

Grenoble, France

Alexandr Botvinkin

Irkutsk State Medical University

Irkutsk, Russia

  1. Moses A, Nelson J, Bagby GC. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood. 1998; 91 (5): 1479-1495
  2. Besson C, Lancar R, Prevot S and al. High risk features contrast with favorable outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. Clin Infect Dis. 2015; 61 (9): 1469-1475.
  3. Leruez-Ville M, Seng R, Morand P, and al. Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma. HIV Med. 2012; 13 (8): 479-87.
  4. Fan H, Kim SC, Chima CO, and al. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J. Med. Virol. 2005; 75: 59-69.
  5. Amiel C, Legoff J, Lescure FX, and al. Epstein-Barr virus load in whole blood correlates with HIV surrogate markers and lymphoma: a French National Cross-Sectional Study. J. Acquir Immune Defic Syndr. 2009; 50(4): 427-429.


Abstract - 32

PDF (Russian) - 0




  • There are currently no refbacks.

Copyright (c) 2016 Semenova T., Germi R., Lupo J., Botvinkin A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies